UroGen Pharma Ltd. (NASDAQ:URGN) Receives $43.70 Consensus Price Target from Analysts

UroGen Pharma Ltd. (NASDAQ:URGN) has earned an average rating of “Buy” from the six brokerages that are currently covering the firm, MarketBeat reports. Five analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $43.70.

A number of equities analysts have issued reports on the stock. EF Hutton Acquisition Co. I raised shares of UroGen Pharma to a “strong-buy” rating in a report on Monday, October 14th. Oppenheimer reissued an “outperform” rating and issued a $40.00 price target on shares of UroGen Pharma in a report on Wednesday, October 16th. HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of UroGen Pharma in a report on Tuesday, October 15th. Finally, D. Boral Capital reissued a “buy” rating and issued a $25.00 price target on shares of UroGen Pharma in a report on Thursday, January 23rd.

Institutional Investors Weigh In On UroGen Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in URGN. China Universal Asset Management Co. Ltd. raised its stake in UroGen Pharma by 90.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock valued at $103,000 after acquiring an additional 3,856 shares during the period. BNP Paribas Financial Markets raised its stake in UroGen Pharma by 221.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock valued at $109,000 after acquiring an additional 5,890 shares during the period. Intech Investment Management LLC bought a new stake in UroGen Pharma in the 3rd quarter valued at about $155,000. Verition Fund Management LLC bought a new stake in UroGen Pharma in the 3rd quarter valued at about $168,000. Finally, SG Americas Securities LLC bought a new stake in shares of UroGen Pharma during the third quarter valued at about $179,000. 91.29% of the stock is currently owned by institutional investors.

UroGen Pharma Price Performance

URGN opened at $11.01 on Friday. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. The company has a market capitalization of $258.23 million, a price-to-earnings ratio of -3.50 and a beta of 1.09. The firm’s fifty day moving average price is $11.18 and its two-hundred day moving average price is $12.81. UroGen Pharma has a 1 year low of $9.78 and a 1 year high of $20.70.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.29. The firm had revenue of $25.20 million for the quarter, compared to analysts’ expectations of $24.22 million. During the same period in the prior year, the firm earned ($0.68) earnings per share. As a group, analysts anticipate that UroGen Pharma will post -3.1 earnings per share for the current fiscal year.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.